



NervGen Pharma Corp.
Policies and Procedures for
Evaluating and Responding to Requests for Expanded Access to NVG-291

NervGen Pharma Corp. (“NervGen”) is committed to developing safe and effective therapies for patients as soon as possible through efficient drug development. NervGen is currently evaluating the efficacy and safety of NVG-291 in a Phase 1b/2a proof-of concept clinical trial in individuals with traumatic spinal cord injury. For more information, click this link: [Phase 1b/2a NVG-291 clinical trial](#). This trial will yield the first results of safety and efficacy of NVG-291 in a spinal cord injury population. NervGen does not have an Expanded Access program at this time and is not accepting requests from healthcare providers for compassionate use.

Contact Information

Questions about NervGen or NVG-291, including the ongoing clinical trial in individuals with traumatic spinal cord injury, can be directed to info@nervgen.com.

Updates on Development of NVG-291

Note that this policy may be updated at any time. In the event that NervGen initiates an Expanded Access program, this website will be updated with a link or reference to the Expanded Access clinical trial record. If you would like to follow NervGen’s progress and updates on the company’s activities, please feel free to subscribe to email alerts at www.nervgen.com.